Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | IL6ST | P40189 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 8/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26640261 | 1.00 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL26640265 | 1.00 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL25409097 | 1.00 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL25409093 | 1.00 | PPARA (0.51) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL21724414 | 0.89 | PPARA (0.52) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL21724552 | 0.89 | PPARA (0.52) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL21724550 | 0.89 | PPARA (0.52) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL21724415 | 0.89 | PPARA (0.52) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL21724412 | 0.89 | PPARA (0.52) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL13316517 | 0.89 | PPARA (0.54) | PPARAIL6STNAAAIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| EP-4214210-A1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | PPARA 2236/4885IL6ST 2657/4885NAAA 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.